



Is transcranial sonography useful for 
diagnosing Parkinson’s disease in 
clinical practice?
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ABSTRACT
Transcranial sonography (TCS) is an emerging ancillary examination for diagnosing Parkinson’s disease (PD). Objective: To evaluate TCS 
features in patients with PD and its mimics, and establish their accuracy in predicting the final clinical diagnosis after follow-up. Methods: 
We retrospectively studied 85 patients with an initial clinical suspicion of PD, atypical parkinsonism or essential tremor, all of whom underwent 
TCS. Two specialists reviewed the follow-up clinical visit records and determined the final clinical diagnosis. The accuracy analysis of the 
TCS was determined using Bayesian statistical methods. Results: The finding of substantia nigra hyperechogenicity (> 20 mm2) showed high 
sensitivity (93.4%) and specificity (86.6%). The positive likelihood ratio showed 6.93-fold greater odds for diagnosing PD than an alternative 
condition when this finding was present. Conclusions: This study revealed the practical usefulness of TCS in differentiating PD from its 
prevalent mimics when the clinical diagnosis was initially unclear. 
Keywords: Parkinson’s disease; parkinsonian disorders; essential tremor; ultrasonography; diagnostic techniques and procedures.
RESUMO
A ultrassonografia transcraniana (UTC) é um exame complementar para diagnóstico de doença de Parkinson (DP). Objetivo: Avaliar as 
características da UTC em pacientes com DP e seus diagnósticos diferenciais e estabelecer a precisão desse exame para o diagnóstico 
clínico de DP após seguimento. Métodos: Avaliou-se retrospectivamente 85 pacientes com suspeita clínica inicial de DP, parkinsonismo 
atípico (PA) ou tremor essencial (TE), todos submetidos a UTC. Um consenso de dois especialistas determinou o diagnóstico clínico final 
após revisar os registros médicos das consultas de seguimento. A precisão do UTC foi calculada usando métodos estatísticos Bayesianos. 
Resultados: O achado de hiperecogenicidade da substância negra (> 20 mm2) mostrou alta sensibilidade (93,4%) e especificidade (86,6%). 
A razão de verossimilhança positiva mostra 6.93 vezes mais chances de diagnosticar DP do que uma condição alternativa, se o achado 
estiver presente. Conclusões: Este estudo demonstra a utilidade prática do UTC na diferenciação de DP de condições clínicas similares 
quando o diagnóstico clínico é inicialmente pouco claro.
Palavras-chave: doença de Parkinson; transtornos parkinsonianos; tremor essencial; ultrassonografia; técnicas e procedimentos diagnósticos.
The diagnosis of idiopathic Parkinson’s disease (PD) remains 
a challenge. Although the clinical opinion of experts remains 
the gold standard1, only 53-75% of their diagnoses agree with 
the definite pathological diagnosis; the major misdiagnoses 
being essential tremor (ET) and atypical parkinsonism (AP)2,3.
As suggested by the European Federation of Neurological 
Societies/Movement Disorder Society – European Section 
recommendations, ancillary examinations should be effective 
in establishing the differential diagnosis of PD4. Imaging and 
biomarkers are urgently required to improve the certainty of 
the current unsatisfactory clinical parameters5.
Transcranial sonography (TCS) is used to evaluate the 
echogenicity of the midbrain and basal ganglia. The sensitivity 
of TCS is high (90%) in discriminating PD cases from not only a 
healthy control group6,7,8 but also major PD mimics, such as ET9,10 
and AP11. The TCS parameters have been standardized in diverse 
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ultrasound models12, replicated with good inter-investigator 
reproducibility7,13, and reproduced in distinct populations14,15. The 
association between substantia nigra (SN) hyperechogenicity 
detected by TCS and the subsequent development of PD8,16,17 
suggests that TCS might enable early diagnosis16,18.
Thus, we aimed to evaluate the diagnostic performance 
of TCS, specifically in patients with an initially-undefined 
etiology for parkinsonian motor symptoms under real clinical 
practice conditions, i.e., in a less-controlled setting than that 
of a clinical trial protocol. 
METHODS
Study population
We retrospectively studied 126 patients who were 
consecutively evaluated in the outpatient clinic of our 
Movement Disorders reference center between January 2015 
and June 2016. These patients presented with parkinsonian 
features (resting tremor, bradykinesia, postural instability or 
rigidity), but did not fulfill all criteria for the diagnosis of PD 
(the UK Brain Bank) at the initial visit. Due to the uncertainty 
of the diagnosis, patients were referred for a TCS examination 
to exclude or confirm the suspicion of idiopathic PD. Among 
all patients who underwent the examination during the 
study period, we excluded 21 patients due to suspicion of 
other clinical diagnoses that we did not want to evaluate in 
this study, such as cerebellar ataxia, Huntington’s disease, 
dystonic tremor, and metabolic or toxic tremor12. We also 
excluded 20 patients who were not able to be evaluated 
with TCS due to insufficient temporal bone windows, which 
technically limited the visualization of the midbrain contour. 
The local ethical standards committee approved the study.
First diagnostic hypothesis
An initial clinical suspicion was defined for each patient 
in order to compare the first clinical impression of the 
neurologist with the final diagnosis after follow-up. This 
initial clinical suspicion was based on the initial clinical data 
acquired by the physician before the TCS was performed. 
None of the patients had a defined clinical diagnosis at 
the time they underwent TCS. However, all patients had 
an initial clinical suspicion of PD, AP (including multiple 
system atrophy and progressive supranuclear palsy) or 
ET. We selected these groups of patients because previous 
studies have shown that TCS can reliably distinguish these 
diagnoses from PD9,11. These patients would thus be the best 
candidates for the TCS examination in a real clinical scenario.
Clinical assessment and diagnosis
Two movement disorder experts reviewed all clinical 
records from at least six months of follow up after the TCS 
examination to determine the definitive clinical diagnosis 
by consensus. In addition to the UK Brain Bank criteria, 
nonmotor symptoms, levodopa response, persistent 
asymmetry, unilateral start, hyposmia, and REM sleep 
behavior disorder, but not the TCS result, were used to define 
a patient as having PD. Medical records were also examined 
for general clinical criteria for Lewy body dementia, 
progressive supranuclear palsy, multiple system atrophy 
and ET19,20,21,22. After the follow-up period, the patients were 
labeled as having ET, PD or AP if a clinical diagnosis was 
achieved. If clinical uncertainty regarding the diagnosis 
remained, the clinicians labeled the patients as having an 
“undefined diagnosis”. In addition, if the exclusion criteria 
for PD (UK Brain Bank) were met and no established clinical 
criteria for AP or ET were present, the patients were labeled 
as “excluded PD”. To perform between-group comparisons, 
the data analysis procedures combined patients with Lewy 
body dementia and PD into the same category - PD - as  Lewy 
body dementia and PD are believed to be distinct clinical 
presentations of the same disease with the same pathological 
substrate but distinct anatomical distribution20. The cases 
that certainly did not represent PD cases (namely, the AP, 
ET and “excluded PD” groups) were labeled altogether as the 
“non-PD” group for some of the analyses. The methodological 
process is outlined in Figure 1.
Acquisition and assessment of TCS images
We performed the TCS examinations according to 
the guidelines of the European Society of Neurosonology 
and Cerebral Hemodynamics23. An Esaote MyLab25Gold 
ultrasound machine (Genoa, Italy) was used along with 
a 2-3.5MHz phased array transducer. The transtemporal 
acoustic bone window was used to assess the midbrain 
bilaterally, and after a 10-degree tilt of the ultrasound beam, 
the examiner also scanned the thalamic axial plane. The 
tissue equalization function and gain adjustments were used 
if necessary23. Characteristic findings are shown in Figure 2.
Based on the published consensus, the SN-TCS was 
scored as “positive” (SN+) if the SN displayed an increased 
echo intensity on at least one side relative to the surrounding 
brainstem tissue with an area value > 20 mm² 18; and scored 
as “markedly positive” with an area value > 25 mm² 18. The 
largest SN planimetric value for each patient was chosen 
for analysis regardless of the side of the measurement. The 
examiner qualitatively classified the lentiform nucleus as 
isoechogenic (LN-) or hyperechogenic (LN+) compared with 
the surrounding tissues. In addition, the third ventricle (V3) 
and lateral ventricle widths were measured.
Statistical analysis
Due to the limited number of participants, we used 
Bayesian methods to analyze our data in order to improve the 
veracity of the results. We applied t-distribution, the Bayesian 
one-way ANOVA24, receiver operating characteristic (ROC) 
curve analysis and the Bayesian test of accuracy as required 
by each situation and as described in the results section. 
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Figure 2. TCS images. (A) Delineation of the hyperechogenic SN in the left hemisphere and mesencephalic plane. (B) Delineation 
of the hyperechogenic SN in the right hemisphere and mesencephalic plane. (C) Delineation of the hyperechogenic LN in the 
thalamic plane. III Ventr: Third ventricle; and S. Nigra: substantia nigra.
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RESULTS
We assessed 85 patients (51 men and 34 women) with a 
mean age of 67 (17-88) years (Table 1). The average clinical 
follow-up time after the TCS exam was 17 months. A defini-
tive clinical diagnosis was determined for 65 (76%) of the 
recruited patients (Figure 1).
The initial clinical suspicion was AP in 18 (21%), ET in 
15 (18%) and PD in 52 (61%) considering all the evaluated 
patients. A definitive diagnosis was achieved in 65 of these 
patients. Regarding the 65 patients with a final diagnosis, the 
initial diagnostic hypothesis was confirmed in 55 of them, rep-
resenting a diagnostic consistency of 85% (Table 2). Twenty-
one percent (n = 7) of the patients who were initially suspected 
to have PD had a different final diagnosis, including ET (n = 2) 
and “excluded PD” (n = 5). Moreover, two (18%) of the patients 
initially classified as ET were later diagnosed as PD.
We applied Bayesian statistics using a robust (t-distribu-
tion) one-way ANOVA to compare the demographic charac-
teristics among the groups with definitive clinical diagnoses, 
and the results did not show statistically significant differ-
ences in the mean ages.
The posterior median of the SN area robust mean was 
defined as the central measure. With the intent of comparing 
the PD and non-PD groups, a difference in the distributions of 
the central tendencies was obtained. Compared to all other 
clinically diagnosed groups, PD patients had the highest SN 
hyperechogenicity area values, which were significantly dif-
ferent compared with those of the other groups. The value 
of the SN hyperechogenic area among all groups that com-
prised the non-PD group did not differ in the between-group 
comparisons (Table 3).
The distribution of the frequencies of SN hyperechogenicity 
(area > 20 mm²) in patients with a final diagnosis of PD and 
in patients who were not diagnosed with PD (non-PD) is 
shown in Table 4. The Bayesian proportions test was applied 
to evaluate the chances of SN hyperechogenicity (> 20 mm²) 
occurrence in the PD and non-PD groups. The PD group had 
an estimated relative frequency of SN hyperechogenicity of 
0.93 [0.85, 0.99], and the non-PD group of 0.13 [0.03, 0.27]. 
The estimated group difference (PD minus non-PD) was 
statistically significant (-0.79 [-0.92, -0.63]), showing that the 
relative frequency of SN hyperechogenicity was higher for 
patients diagnosed with PD.
Lentiform nucleus hyperechogenicity (LN+) was observed 
in 10% (n = 4) of patients diagnosed with PD and 22% (n = 2) 
of patients diagnosed with AP. Moreover, enlargement of the 
V3 was observed in 11% (n = 1) of patients in the AP group and 
5% (n = 2) of patients in the PD group. These features have been 
used in other studies to help distinguish between PD and AP24. 
However, when the Bayesian proportions test was used to assess 
the association of LN+ or V3 enlargement with the diagnoses of 
AP and PD, a between-group difference was not observed.
The Bayesian accuracy test was applied to evaluate 
the diagnostic accuracy of TCS based on the following 
central question: “Is SN hyperechogenicity a finding that 
could predict a clinical diagnosis of PD in this cohort after 
follow-up?”. Using the cut-off value of 20 mm², the finding 
of SN hyperechogenicity showed robust positive likelihood 
ratios (6.93) for a prospective PD clinical diagnosis when 
the group with a definitive clinical diagnosis of PD was 
compared with the group diagnosed with alternative clinical 
disorders (non-PD group). When using the cut-off value of 
Table 1. Epidemiological data.





Atypical parkinsonism 18 21.2
Parkinson’s disease 52 61.2
Essential tremor 15 17.6
Final diagnosis
Atypical parkinsonism 9 10.6
Undefined 20 23.5
Excluded Parkinson’s disease 6 7.1
PD or Lewy body dementia 39 45.9
Essential tremor 11 12.9
Symptom side
Right side 45 52.9
Left side 23 27.1





Table 2. Diagnosis distribution.
Initial clinical suspicion Final clinical diagnosis
Parkinson’s disease 
(n = 52), 61%
Parkinson’s disease (n = 37), 71%
Essential tremor (n = 2), 4%
Excluded Parkinson’s (n = 5), 10%
Undefined (n = 8), 15%
Atypical parkinsonism 
(n = 18), 21%
Atypical (n = 9), 50%
Undefined (n = 9), 50%
Essential tremor 
(n = 15), 18%
Essential tremor (n = 9), 60%
Parkinson’s disease (n = 2), 13%
Excluded Parkinson’s (n = 1), 7%
Undefined (n = 3), 20%
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25 mm², as suggested by other studies11, SN hyperecho-
genicity revealed an even higher positive likelihood ratio (LR) 
(12.87). Moreover, the positive predictive value, sensitivity, 
and specificity of this measure for PD diagnosis were also 
high (greater than 90%), as shown in Table 5.
In addition, when applying the same accuracy test, hyper-
echogenic LN or V3 enlargement displayed high sensitivity 
for identifying AP (0.884 [0.764, 0.958] and 0.934 [0.830, 0.984], 
respectively) with low specificity (0.163 [0.025, 0.445] and 
0.258 [0.066, 0.556], respectively).
The Bayesian estimate for a ROC curve25 revealed an 
area under the curve of 0.945 [0.867, 0.982], implying that SN 
hyperechogenicity exhibited reasonable accuracy for a pro-
spective PD diagnosis. In addition, the optimal SN planim-
etry cut-off value to distinguish between the PD and non-PD 
groups using our equipment and methods was estimated to 
be 21.4 mm² (Figure 3). The values regarding the diagnostic 
values for PD x ET and PD x AP are shown in Table 6.
DISCUSSION
Even in specialized movement disorder clinics, approxi-
mately 10–25% of PD patients may be misdiagnosed using 
standard clinical diagnostic criteria when compared with 
autopsy findings2,5. This rate of misdiagnosis emphasizes the 
need for complementary methods and biomarkers for diag-
nosing PD. A similar demand exists for reliable statistical 
approaches, such as Bayesian methods, to enable more accu-
rate measurements of the power of these markers for diag-
nosing PD26.
Currently, TCS is consolidated as a practical diagnostic 
tool that can discriminate between PD and PD mimics in 
late clinical stages9,11. However, in clinical practice, one of the 
difficulties in a movement disorder clinic is distinguishing 
between PD, AP and ET in early clinical stages. Likewise, TCS 
also seems to be valid in the differential diagnosis of PD even 
in the early stages. If the patient presents with an incomplete 
clinical syndrome, the finding of a hyperechogenic SN sug-
gests a diagnosis of PD, whereas the absence of this result 
suggests a diagnosis of an alternative condition16,18. In this 
retrospective cohort study, we have confirmed that TCS can 
be helpful in distinguishing between PD and AP at the first 
diagnostic evaluation as well as between the prospective 
diagnoses of PD and ET in a practical clinical scenario. 
Although the clinical follow-up period in our study 
was a minimum of six months, most of the patients had 
complained of symptoms for more than three years. However, 
not all patients in the definitively-diagnosed group had a five-
year follow-up period, and some patients had not received 
a final diagnosis by the end of this study (n = 20) because 
they still did not fulfill all the diagnostic criteria. The rate 
of disagreement between the first clinical suspicion and the 
definitive diagnosis was 14% (n = 9), which is consistent with 
the rates previously described for this scenario5.
The TCS results considering the SN > 20mm² agreed 
with the final clinical diagnosis in all of the cases in which 
the clinical diagnosis had to be changed from PD to non-PD 
(n = 7) or from ET to PD (n = 2). Although the TCS results 
were not considered when these final clinical diagnoses were 
Table 3. Post hoc analysis of the robust Bayesian t-test and one-way ANOVA.
Group Posterior median of the SN area robust mean [HDI – 95% and σ]
Difference between posterior medians of the SN 
area robust mean [HDI – 95% and η]
Non-PD μ = 16.6 [15.4, 17.8], σ = 2.7 [1.6, 4.1] vs. PD = -18* [-22, -15]; η = -2.80 [-3.7, -1.8]
PD μ = 34.6 [31.6, 37.9], σ = 9.4 [7.1, 12.0] vs. AP = 15.3 [9.5, 20.5]; η = 0.66 [-0.4, 1.8]
AP μ = 19.2 [14.9, 24.0], σ = 5.9 [2.6, 10.4] vs. ET = -2.7 [-7.5, -1.8]; η = -0.60 [-1.5, 0.4]
ET μ = 16.6 [15.0, 18.1], σ = 2.2 [1.3, 3.8] vs. PD = 18* [14.2, 21.3]; η = 2.61 [1.8, 3.5]
EPD μ = 14.7 [11.9, 17.8], σ = 2.9 [1.3, 6.0] vs. PD = 19.8* [15.5, 24.1]; η = 2.84 [1.9, 3.5]
EPD: excluded PD; PD: Parkinson’s disease; AP: atypical parkinsonism; ET: essential tremor; non-PD: AP+ET+EPD; HDI: high-density interval; σ: posterior median 
of the robust standard deviation; η: posterior median of the effect size. *Significant between-group difference in the posterior medians. Note: The results from 
the Bayesian statistical analysis were considered to be statistically significant if the highest density intervals (HDI) did not cross the value zero.
Table 4. Results of TCS and the definitive clinical diagnoses.
Variable SN+ SN-
Parkinson’s disease 37 (32) 2 (6)
Non-PD 3 (1) 23 (24)
The numbers in parentheses represent data calculated using the alternative 
cut-off value of 25 mm². 
Table 5. Bayesian accuracy of the diagnostic tests (Parkinson’s 
disease vs. alternative diagnosis).
Parameters
SN 
(cut-off = 20 mm²)
SN 





LR negative 0.078 [0.02, 0.20] 0.18 [0.08, 0.33]
LR positive 6.93 [3.15, 22.15] 12.87 [4.16, 89.45]
Negative predictive value 0.90 [0.75, 0.98] 0.79 [0.63, 0.90]
Positive predictive value 0.91 [0.80, 0.98] 0.95 [0.85, 0.99]
Sensitivity 0.93 [0.83, 0.98] 0.83 [0.70, 0.93]
Specificity 0.87 [0.71, 0.96] 0.94 [0.80, 0.99]
LR: likelihood ratio.
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determined, our study results highlight the suitability of TCS 
in enabling clinicians to reach the proper diagnosis earlier, 
as SN hyperechogenicity was highly predictive of the subse-
quent fulfillment of the UK Brain Bank criteria. Likewise, the 
absence of SN hyperechogenicity predicted the subsequent 
clinical characterization of a non-PD clinical diagnosis. 
The high positive predictive value reported in the pres-
ent study (91.2%) is consistent with the results from a study 
using a prospective methodology and preselected patients 
(92.9%). It is also a plausible argument for the early use of 
this test in clinical practice, namely, when most of the motor 
and nonmotor symptoms have not yet manifested16. Besides 
being a study carried out in a clinical practice scenario, our 
results (89.9%) also reproduced a high negative predictive 
value (85.7%), revealing the efficacy of TCS in excluding a PD 
diagnosis based on negative results18.
The LR is a measure of how the test would influence the 
diagnostic decision, and considers sensitivity and specific-
ity, but is not affected by the disease prevalence27. Although 
underused, the LR can refine the clinical diagnosis28. The 
LR considers the probability that the patient will present 
the characteristic of interest before the test (in our case, a 
PD diagnosis) and the extent to which the test can increase 
the probability of the characteristic occurrence27. The LR has 
been simplified by an estimate that can be used regardless of 
the pretest probability value. A positive likelihood ratio (LR+) 
value of 6, for example, represents an increase of 35% over the 
pretest probability that the characteristic will occur based on 
the test results27. A positive LR ranging from 2-5 represents a 
small increase in post-test probability that the characteris-
tic will occur, whereas values from 5-10 indicate a moderate 
increase in the post-test probability, and values greater than 
10 indicate a large increase in the post-test probability28. In 
this study, a significant increase (6.93 times) was observed in 
the odds that an undiagnosed case of parkinsonism would 
receive a subsequent PD diagnosis (based on UK Brain Bank 
criteria) if a hyperechogenic SN (> 20 mm²) was observed. 
This finding reflects an increase of approximately 35% from 
the previous post-test probability of diagnosis. With findings 
of SN > 25 mm², the LR+ is even higher (12.87) and represents 
an increase of more than 45% for the probability of receiv-
ing a PD diagnosis. Similar positive LR values have also been 
described when evaluating the odds of an asymptomatic sub-
ject prospectively developing specific PD symptoms when SN 
hyperechogenicity was observed25. These data reveal how a 
clinician can apply the results of SN hyperechogenicity evalu-
ation in a simple and accurate manner when assessing a pos-
sible case of PD.
In the present study, most likely due to our small sample 
size, the isolated finding of LN hyperechogenicity in the TCS 
examination was not a unique feature that could differentiate 
PD from AP, as already described in other studies11. However, in 
LN hyperechogenicity, this feature, when combined with the 
Figure 3. Graphic representation of the optimal SN planimetry cut-off value for our population when comparing PD and 
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Table 6. Bayesian ROC curve.




50 0.963 20.0 0.939 0.952
(n = 11 x n = 39)
AP x PD
48 0.858 21.9 0.910 0.691
(n = 9 x n = 39)
 Non-PD x PD
65 0.928 21.4 0.896 0.890
(n = 26 x n = 39)
PD: Parkinson’s disease; AP: atypical parkinsonism; ET: essential tremor; 
non-PD: non-Parkinson’s disease.
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absence of SN hyperechogenicity, which occurred in two cases, 
was identified only in patients with a final clinical diagnosis 
of AP. This finding supports previous reports claiming that 
the combination of LN without SN hyperechogenicity is a 
good predictor of an AP diagnosis11. In addition, also probably 
due to the sample size, the combination of V3 enlargement 
and LN hyperechogenicity (applied here with the intent to 
predict a diagnosis of PD or AP) showed low sensitivity and 
high specificity, which is inconsistent with published data, 
showing that the association of LN+ and V3 enlargement has 
a sensitivity and specificity of 77% in distinguishing between 
AP and PD11,29.
Regarding the weaknesses of the method, patients with 
corticobasal syndrome and Lewy body dementia, two other 
relevant PD mimics, also typically show SN hyperecho-
genicity; thus, TCS is not a useful tool for differentiating 
among diagnoses of PD, Lewy body dementia, and cortico-
basal syndrome23. Nevertheless, some authors consider PD 
and Lewy body dementia as two entities on the same spec-
trum of Lewy body disorders21. Furthermore, corticobasal 
syndrome has clinical features (e.g., myoclonus, asymmetric 
dystonia, apraxia, and alien hand phenomenon) that are dis-
tinguishable from those of PD solely on a clinical basis, which 
minimizes the issue from this limitation of TCS. The clini-
cal use of TCS might also be limited by the need for operator 
experience and training in addition to the technical difficul-
ties in imaging through the temporal window. When trained 
operators use the correct technique, the proportion of inac-
cessible bone windows does not exceed 20%23. In our sample, 
this proportion was 16% (n = 20). 
Other neuroimaging methods, such as MRI (nigrosome-1 
and neuromelanin imaging, DTI, and SWI), dopamine trans-
porter brain SPECT, MIBG cardiac SPECT or18 F-DOPA PET, 
are expensive and not readily available and may involve expo-
sure to radiation23. The absence of an accurate, economical 
and practical method (or biomarker) for early confirmation 
of a PD diagnosis is a current medical issue; meaning that a 
significant proportion of patients with early-stage PD are not 
diagnosed until specific milestones of the natural history of 
the disease are reached30. 
We recognize that the present study is a retrospective 
cohort study with a small sample size and relatively short 
follow-up time. Despite these limitations, the strength of the 
association between SN hyperechogenicity and the predic-
tion of the clinical diagnosis of PD suggests that TCS is an 
ancillary technique that can be used, particularly in coun-
tries with limited resources. This was the first Brazilian study 
to use TCS to distinguish PD from AP and ET in a clinical 
practice scenario. In addition to the other case series of PD 
patients evaluated with TCS in Brazil14,15, our study highlights 
TCS as a nonradiation-dependent, accessible and safe diag-
nostic tool that can be utilized in Brazilian reality.
In conclusion, our results reinforce the previously-
reported power of TCS in hastening the diagnosis of PD. This 
retrospective cohort study suggests that TCS is suitable for 
use in a real-world clinical scenario and provides support-
ing evidence for the use of TCS as a complementary diagnos-
tic tool in the initial neurological evaluation of patients who 
present with bradykinesia, rigidity, and tremor31.
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